[1]林松荣,张 磊,罗金现,等.DNA甲基化修饰在甲状腺癌中的研究进展[J].陕西医学杂志,2021,50(2):254-封3.[doi:DOI:10.3969/j.issn.1000-7377.2021.02.033]
 LIN Songrong,ZHANG Lei,LUO Jinxian,et al.Research progress of DNA methylation in thyroid cancer[J].,2021,50(2):254-封3.[doi:DOI:10.3969/j.issn.1000-7377.2021.02.033]
点击复制

DNA甲基化修饰在甲状腺癌中的研究进展

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
50
期数:
2021年2期
页码:
254-封3
栏目:
综述
出版日期:
2021-02-05

文章信息/Info

Title:
Research progress of DNA methylation in thyroid cancer
作者:
林松荣12张 磊2罗金现2秦克旺2
(1.南方医科大学第二临床医学院,广东 广州 510317; 2.广东省第二人民医院,广东 广州 510317)
Author(s):
LIN SongrongZHANG LeiLUO JinxianQIN Kewang
(The Second Clinical Medical School of Southern Medical University,Guangzhou 510317,China)
关键词:
甲状腺癌 DNA甲基化 表观遗传学 抑癌基因 原癌基因 甲状腺特异性基因
Keywords:
hyroid cancer DNA methylation Epigenetics Tumor suppressor gene Proto oncogene Thyroid-specific gene
分类号:
R 736.1
DOI:
DOI:10.3969/j.issn.1000-7377.2021.02.033
文献标志码:
A
摘要:
甲状腺癌是常见的内分泌系统恶性肿瘤,目前的研究发现甲状腺癌的发生与基因突变和表观遗传学改变有关。DNA甲基化是重要的表观遗传修饰之一,在调节甲状腺癌的进展中发挥着关键作用。随着表观遗传学研究的不断深入,DNA甲基化有望被开发为甲状腺癌诊断、预后和治疗应用方面的临床生物标志物。现对近年来DNA甲基化在甲状腺癌中的研究进展进行综述。
Abstract:
Thyroid cancer is a common malignant tumor of the endocrine system.Current studies have found that the occurrence of thyroid cancer is related to gene mutation and epigenetic changes.DNA methylation is one of the important epigenetic modifications,which plays a key role in regulating the progression of thyroid cancer.With the deepening of epigenetics research,DNA methylation is expected to be developed as a clinical biomarker for the diagnostic,prognostic and therapeutic application of thyroid cancer.This article summarizes the research progress of DNA methylation in thyroid cancer in recent years.

参考文献/References:

[1] Kitahara CM,Devesa SS,Sosa JA.Increases in thyroid cancer incidence and mortality-reply[J].JAMA,2017,318(4):390-391.
[2] Brown TC,Juhlin CC,Healy JM,et al.Frequent silencing of RASSF1A via promoter methylation in follicular thyroid hyperplasia:A potential early epigenetic susceptibility event in thyroid carcinogenesis[J].JAMA Surgery,2014,149(11):1146-1152.
[3] Kunstman JW,Korah R,Healy JM,et al.Quantitative assessment of RASSF1A methylation as a putative molecular marker in papillary thyroid carcinoma[J].Surgery,2013,154(6):1255-1262.
[4] Stephen JK,Chen KM,Merritt J,et al.Methylation markers for early detection and differentiation of follicular thyroid cancer subtypes[J].Cancer and Clinical Oncology,2015,4(2):1-12.
[5] Alvarez-Nunez F,Bussaglia E,Mauricio D,et al.PTEN promoter methylation in sporadic thyroid carcinomas[J].Thyroid,2006,16(1):17-23.
[6] Hou P,Ji M,Xing M.Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors[J].Cancer,2008,113(9):2440-2447.
[7] Jackson HW,Defamie V,Waterhouse P,et al.TIMPs:Versatile extracellular regulators in cancer[J].Nature Reviews Cancer,2017,17(1):38.
[8] Hu S,Liu D,Tufano RP,et al.Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer[J].International Journal of Cancer,2006,119(10):2322-2329.
[9] 黄铀新,罗耀玲,任志平,等.循环肿瘤DNA中TSHR、RARβ2和RASSF1A启动子甲基化在甲状腺癌早期诊断中的价值[J].江西医药,2017,52(11):1117-1119,1127.
[10] Kiseljak-Vassiliades K,Xing M.Association of cigarette smoking with aberrant methylation of the tumor suppressor gene RARβ2 in papillary thyroid cancer[J].Frontiers in Endocrinology,2011,2:99.
[11] Wong SHM,Fang CM,Chuah LH,et al.E-cadherin:Its dysregulation in carcinogenesis and clinical implications[J].Critical Reviews in Oncology/Hematology,2018,121:11-22.
[12] Jensen K,Patel A,Hoperia V,et al.Dynamic changes in E-cadherin gene promoter methylation during metastatic progression in papillary thyroid cancer[J].Experimental and Therapeutic Medicine,2010,1(3):457-462.
[13] Shen S,Chen X,Li H,et al.MLH1 promoter methylation and prediction/prognosis of gastric cancer:A systematic review and meta and bioinformatic analysis[J].Journal of Cancer,2018,9(11):1932.
[14] 陆晓筱,葛明华,凌志强,等.甲状腺乳头状癌组织中hMLH1基因启动子甲基化及其临床意义[J].中华肿瘤杂志,2013,35(11):833-836.
[15] Santos JC,Bastos AU,Cerutti JM,et al.Correlation of MLH1 and MGMT expression and promoter methylation with genomic instability in patients with thyroid carcinoma[J].Bmc Cancer,2013,13(1):79.
[16] Wang P,Pei R,Lu Z,et al.Methylation of p16 CpG islands correlated with metastasis and aggressiveness in papillary thyroid carcinoma[J].Journal of the Chinese Medical Association,2013,76(3):135-139.
[17] 戴亚丽,张 帆,叶 静,等.乳头状甲状腺癌p16基因蛋白表达及启动子甲基化的研究[J].广东医学,2010,31(14):1804-1807.
[18] Brait M,Loyo M,Rosenbaum E,et al.Correlation between BRAF mutation and promoter methylation of TIMP3,RARβ2 and RASSF1A in thyroid cancer[J].Epigenetics,2012,7(7):710-719.
[19] Botezatu A,Iancu IV,Plesa A,et al.Methylation of tumour suppressor genes associated with thyroid cancer[J].Cancer Biomarkers,2019,25(1):53-65.
[20] Klein HEN,Zafon C,Villalmanzo N,et al.Increased global DNA hypomethylation in distant metastatic and dedifferentiated thyroid cancer[J].J Clin Endocrinol Metab,2018,103(2):397-406.
[21] Rodríguez RS,Fernández AF,Fernández-Morera JL,et al.DNA methylation signatures identify biologically distinct thyroid cancer subtypes[J].J Clin Endocrinol Metab,2013,98(7):2811-2821.
[22] Khan MS,Pandith AA,Masoodi SR,et al.Epigenetic silencing of TSHR gene in thyroid cancer patients in relation to their BRAF V600E mutation status[J].Endocrine,2014,47(2):449-455.
[23] Galrao AL,Camargo RY,Friguglietti CU,et al.Hypermethylation of a new distal sodium/iodide symporter(NIS)enhancer(NDE)is associated with reduced NIS expression in thyroid tumors[J].J Clin Endocrinol Metab,2014,99(6):944-952.
[24] Niu H,Yang J,Yang K,et al.The relationship between RASSF1A promoter methylation and thyroid carcinoma:A meta-analysis of 14 articles and a bioinformatics of 2 databases(PRISMA)[J].Medicine,2017,96(46):e8630.
[25] Stephen JK,Chen KM,Merritt J,et al.Methylation markers differentiate thyroid cancer from benign nodules[J].Journal of Endocrinological Investigation,2018,41(2):163-170.
[26] Siraj AK,Pratheeshkumar P,Parvathareddy SK,et al.Prognostic significance of DNMT3A alterations in Middle Eastern papillary thyroid carcinoma[J].European Journal of Cancer,2019,117:133-144.
[27] Vitale G,Dicitore A,Pepe D,et al.Synergistic activity of everolimus and 5-aza-2'-deoxycytidine in medullary thyroid carcinoma cell lines[J].Molecular Oncology,2017,11(8):1007-1022.
[28] Zafon C,Gil J,Pérez-González B,et al.DNA methylation in thyroid cancer[J].Endocr Relat Cancer,2019,26(7):415-439.

相似文献/References:

[1]陈宏月,李兴江△.甲状腺全切除术对甲状腺癌患者血清血管内皮生长因子、可溶性Fas受体、可溶性Fas受体配体mRNA表达的影响研究[J].陕西医学杂志,2020,49(1):96.
 CHEN Hongyue,LI Xingjiang..Effect of total thyroidectomy on mRNA expression levels of VEGF,sFas and sFasL in serum of patients with thyroid cancer[J].,2020,49(2):96.
[2]谢新静,李忠原.实时剪切波弹性成像联合甲状腺球蛋白抗体检测在甲状腺癌诊断中的应用研究[J].陕西医学杂志,2021,50(2):154.[doi:DOI:10.3969/j.issn.1000-7377.2021.02.007]
 XIE Xinjing,LI Zhongyuan.Application of real-time shear wave elastography combined with Tg-Ab detection in diagnosis of thyroid cancer[J].,2021,50(2):154.[doi:DOI:10.3969/j.issn.1000-7377.2021.02.007]
[3]苏永健,陈梦丽,李嘉铃,等.YTHDF基因DNA甲基化与乙肝疫苗低/无免疫应答水平关系研究[J].陕西医学杂志,2022,51(9):1076.[doi:DOI:10.3969/j.issn.1000-7377.2022.09.007]
 SU Yongjian,CHEN Mengli,LI Jialing,et al.Relationship between DNA methylation of YTHDF gene and low/no immune response level of hepatitis B vaccine[J].,2022,51(2):1076.[doi:DOI:10.3969/j.issn.1000-7377.2022.09.007]
[4]石维超,张少波.甲状腺癌病理微血管密度与颈部淋巴结转移相关性研究[J].陕西医学杂志,2022,51(11):1449.[doi:DOI:10.3969/j.issn.1000-7377.2022.11.031]
 SHI Weichao,ZHANG Shaobo.Correlation between pathological microvessel density and cervical lymph node metastasis in thyroid cancer[J].,2022,51(2):1449.[doi:DOI:10.3969/j.issn.1000-7377.2022.11.031]
[5]王媛媛,朱 静,刘娜娜,等.溶质载体家族1成员5及谷氨酰胺酶2对人甲状腺癌细胞体外恶性行为的影响及机制研究[J].陕西医学杂志,2023,52(3):344.[doi:DOI:10.3969/j.issn.1000-7377.2023.03.023]
 WANG Yuanyuan,ZHU Jing,LIU Nana,et al.Effect of solute carrier family 1 member 5 and glutaminases 2 on malignant behavior of human thyroid cancer cells in vitro and its mechanism[J].,2023,52(2):344.[doi:DOI:10.3969/j.issn.1000-7377.2023.03.023]
[6]杨 标,李 慧,吴 盈,等.胎盘组织肿瘤坏死因子-α基因表观遗传修饰与胎盘血肿患者发生早产相关性研究[J].陕西医学杂志,2025,54(2):263.[doi:DOI:10.3969/j.issn.1000-7377.2025.02.025]
 YANG Biao,LI Hui,WU Ying,et al.Correlation between epigenetic modification of TNF-α gene in placental tissues and the occurrence of preterm birth in patients with placental hematoma[J].,2025,54(2):263.[doi:DOI:10.3969/j.issn.1000-7377.2025.02.025]
[7]宋传伟,刘兆芳,刘兆琳.血清Tg、TgAb、ZEB1水平对甲状腺癌术后清甲治疗患者疾病复发的预测价值[J].陕西医学杂志,2025,54(6):825.[doi:DOI:10.3969/j.issn.1000-7377.2025.06.020]
 SONG Chuanwei,LIU Zhaofang,LIU Zhaolin.Predictive value of Tg,TgAb and ZEB1 levels for recurrence of thyroid cancer in patients with thyroid remnant ablation after thyroidectomy[J].,2025,54(2):825.[doi:DOI:10.3969/j.issn.1000-7377.2025.06.020]
[8]华春波,陶宣辰,吕家誉,等.甲状腺癌组织miR-338、miR-143表达及其与患者临床病理特征和预后的关系[J].陕西医学杂志,2025,54(6):830.[doi:DOI:10.3969/j.issn.1000-7377.2025.06.021]
 HUA Chunbo,TAO Xuanchen,LYU Jiayu,et al.Expression of miR-338 and miR-143 in thyroid cancer tissues and their relationship with clinicopathologic features and prognosis[J].,2025,54(2):830.[doi:DOI:10.3969/j.issn.1000-7377.2025.06.021]

更新日期/Last Update: 2021-01-28